Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

NCT04438382 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04438382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04438382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Terminated
Start date
January 7, 2021
Completion date
May 26, 2026
Enrollment
1 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm, steroid-refractory pneumonitis